Early-onset generalized dystonia
MONDO:0100016A generalized isolated dystonia characterized by early-onset, which may be clinically indistinguishable from DYT-TOR1A and may be the most common cause of early-onset generalized dystonia, at least outside the Askenazi Jewish population.
Also known as: DYT-KMT2B, early-onset, generalised dystonia with mild syndromic features, early-onset, generalized dystonia with mild syndromic features, early-onset generalised isolated dystonia, early-onset generalized isolated dystonia
18 clinical trials for this condition and its sub-types, 2 tagged with Early-onset generalized dystonia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Early-onset generalized dystonia
-
1 sub-type
-
New drug cocktail takes aim at Hard-to-Treat leukemia
Disease control Recruiting nowThis early-stage trial is testing a new drug called ziftomenib combined with standard chemotherapy or another targeted drug for people with relapsed or treatment-resistant acute myeloid leukemia (AML) that has specific genetic changes. The main goal is to see if these combination…
Phase 1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug cocktail aims to tackle tough leukemia
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called ziftomenib alongside standard treatments for acute myeloid leukemia (AML) in people with specific gene mutations. About 420 participants with newly diagnosed or relapsed AML will be assigned to one of three treatment a…
Phase 1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC